Key Segments:
By Indication
-
Plaque Psoriasis
-
Psoriatic Arthritis
-
Ankylosing Spondylitis
-
Non-Radiographic Axial Spondyloarthritis
-
Others
By Route of Administration
-
Subcutaneous
-
Intravenous
-
Others
By Distribution Channel
-
Hospital Pharmacies
-
Retail Pharmacies
-
Specialty Pharmacies
-
Online Pharmacies
By Product Type
-
Originator Brand
-
Biosimilars
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The market includes Novartis, Celltrion, CSPC Pharmaceutical Group, Bio-Thera Solutions, among others. These companies compete through the originator brand, a growing field of secukinumab biosimilar candidates, and rival IL-17, IL-23 and TYK2 inhibitor franchises.
The main opportunities lie in licensing and commercialization partnerships that let biosimilar developers reach new geographic markets quickly, and in first-mover positioning within regions where biosimilar competition against Cosentyx has not yet arrived.
The key growth factor is the unusually large number of secukinumab biosimilar programs advancing through regulatory stages simultaneously, which is expected to accelerate competitive entry once the first approval is secured.
By indication, the Plaque Psoriasis segment dominated the market with approximately 52.40% share in 2025, reflecting its status as secukinumab's original and most established approved use.
North America dominated the market with approximately 45.80% share in 2025, supported by the deepest established prescriber base for IL-17 and IL-23 inhibitors. Asia Pacific is the fastest-growing region with a projected CAGR of 8.60% from 2026 to 2035.
